Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Verekitug · UPB-101, ASP-7266

Monoclonal antibody · developed by Upstream Bio

Phase 2 Most advanced trial
UPB Developer
3 Registered trials

What is Verekitug?

Verekitug (UPB-101, ASP-7266) is a subcutaneously injected agent studied in severe asthma, asthma, and chronic rhinosinusitis with nasal polyps.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
UPB-101, ASP-7266, Formerly ASP7266
Drug type
Monoclonal antibody
Therapy area
Ear, nose & throat, Respiratory
Developer
Upstream Bio Inc. (UPB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
T1NAO7YDA7

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06966479 Phase 2 Severe Asthma Active not recruiting UPB
NCT06164704 Phase 2 Chronic Rhinosinusitis With Nasal Polyps Completed UPB
NCT05448651 Phase 1 Asthma Completed UPB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Severe AsthmaAsthmaChronic Rhinosinusitis With Nasal Polyps

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the UPB page.

Follow UPB, the company behind Verekitug

See UPB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

UPB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.